BridgeBio Pharma (BBIO) Cost of Revenue (2021 - 2026)

BridgeBio Pharma (BBIO) has 6 years of Cost of Revenue data on file, last reported at $9.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 276.62% year-over-year to $9.9 million; the trailing twelve-month figure through Mar 2026 stood at $28.3 million (up 377.48% YoY), and the FY2025 full-year result was $21.0 million, up 440.54% from the prior year.
• Cost of Revenue rose to $9.9 million in Q1 2026, from $8.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $9.9 million in Q1 2026 to a low of $598000.0 in Q3 2023.
• A 5-year average of $2.4 million and a median of $700000.0 in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue sank 58.28% in 2022 and jumped 997.49% in 2025, its largest moves.
• Tracing BBIO's Cost of Revenue over 5 years: stood at $647000.0 in 2022, then retreated by 7.57% to $598000.0 in 2023, then soared by 248.49% to $2.1 million in 2024, then jumped by 289.01% to $8.1 million in 2025, then rose by 22.6% to $9.9 million in 2026.
• Business Quant data shows BBIO's Cost of Revenue at $9.9 million in Q1 2026, $8.1 million in Q4 2025, and $6.6 million in Q3 2025.